These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 22004484

  • 1. Treatment of imported New World cutaneous leishmaniasis in Germany.
    Harms G, Scherbaum H, Reiter-Owona I, Stich A, Richter J.
    Int J Dermatol; 2011 Nov; 50(11):1336-1342. PubMed ID: 22004484
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers.
    Eichner S, Thoma-Uszynski S, Herrgott I, Sebald H, Debus A, Tsianakas A, Ehrchen J, Harms G, Simon M, Sunderkötter C, Bogdan C.
    Eur J Dermatol; 2013 Apr 01; 23(2):218-23. PubMed ID: 23557633
    [Abstract] [Full Text] [Related]

  • 4. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
    de Morais-Teixeira E, Aguiar MG, Soares de Souza Lima B, Ferreira LA, Rabello A.
    J Antimicrob Chemother; 2015 Dec 01; 70(12):3283-90. PubMed ID: 26346991
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I, López L, Sánchez X, Mestra L, Rojas C, Rodríguez E.
    Am J Trop Med Hyg; 2010 Aug 01; 83(2):351-6. PubMed ID: 20682881
    [Abstract] [Full Text] [Related]

  • 6. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
    Gagini T, de Oliveira Schubach A, de Fatima Madeira M, Maria Valete-Rosalino C, Fernandes Pimentel MI, da Silva Pacheco R.
    Parasite; 2017 Aug 01; 24():34. PubMed ID: 28959938
    [Abstract] [Full Text] [Related]

  • 7. Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
    Mosimann V, Neumayr A, Hatz C, Blum JA.
    Infection; 2013 Dec 01; 41(6):1177-82. PubMed ID: 23835701
    [Abstract] [Full Text] [Related]

  • 8. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
    Romero GA, Guerra MV, Paes MG, Macêdo VO.
    Am J Trop Med Hyg; 2001 Nov 01; 65(5):456-65. PubMed ID: 11716098
    [Abstract] [Full Text] [Related]

  • 9. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.
    Neves LO, Talhari AC, Gadelha EP, Silva Júnior RM, Guerra JA, Ferreira LC, Talhari S.
    An Bras Dermatol; 2011 Nov 01; 86(6):1092-101. PubMed ID: 22281895
    [Abstract] [Full Text] [Related]

  • 10. Disseminated Leishmaniasis, a Severe Form of Leishmania braziliensis Infection.
    Machado PRL, Lago A, Cardoso TM, Magalhaes A, Carvalho LP, Lago T, Carvalho AM, Costa R, Carvalho EM.
    Emerg Infect Dis; 2024 Mar 01; 30(3):510-518. PubMed ID: 38407142
    [Abstract] [Full Text] [Related]

  • 11. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A.
    Acta Trop; 2007 Jul 01; 103(1):33-40. PubMed ID: 17586452
    [Abstract] [Full Text] [Related]

  • 12. Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.
    Spinicci M, Zammarchi L, Gramiccia M, Di Muccio T, Bartolozzi D, Corsi P, Trotta M, Bartoloni A.
    J Travel Med; 2021 Aug 27; 28(6):. PubMed ID: 32918547
    [No Abstract] [Full Text] [Related]

  • 13. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH, Frézard F, Pereira NP, Moura AS, Ramos LMQC, Carvalho GB, Rocha MOC.
    Trop Med Int Health; 2019 Apr 27; 24(4):380-391. PubMed ID: 30681239
    [Abstract] [Full Text] [Related]

  • 14. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
    Saldanha AC, Romero GA, Merchan-Hamann E, Magalhães AV, Macedo Vde O.
    Rev Soc Bras Med Trop; 1999 Apr 27; 32(4):383-7. PubMed ID: 10495667
    [Abstract] [Full Text] [Related]

  • 15. Use of topical rSm29 in combination with intravenous meglumine antimoniate in the treatment of cutaneous leishmaniasis: A randomized controlled trial.
    Lago T, Peixoto F, Mambelli F, Carvalho LP, Guimarães LH, Carvalho AM, Cardoso L, Machado PRL, Scott P, Lago J, Andrade JM, Fahel JS, Oliveira SC, Carvalho EM.
    Int J Infect Dis; 2024 Oct 27; 147():107206. PubMed ID: 39147194
    [Abstract] [Full Text] [Related]

  • 16. Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.
    Hamzavi SS, Sanaei Dashti A, Kadivar MR, Pouladfar G, Pourabbas B.
    Pediatr Infect Dis J; 2018 Mar 27; 37(3):275-277. PubMed ID: 29424815
    [Abstract] [Full Text] [Related]

  • 17. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, Juarez M, Taranto NJ.
    Am J Trop Med Hyg; 2007 Oct 27; 77(4):640-6. PubMed ID: 17978064
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
    Castro MDM, Cossio A, Velasco C, Osorio L.
    PLoS Negl Trop Dis; 2017 Apr 27; 11(4):e0005515. PubMed ID: 28379954
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness study of therapeutic approaches for mucosal leishmaniasis.
    Carvalho JP, Cota G, Freire ML, Galvão EL, Silva SN, Assis TSM.
    Cad Saude Publica; 2024 Apr 27; 40(8):e00132523. PubMed ID: 39166558
    [Abstract] [Full Text] [Related]

  • 20. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis.
    Mohammad N, Sagheer F, Paracha MM, Khan AQ, Naseem S, Wasim M.
    J Ayub Med Coll Abbottabad; 2022 Apr 27; 34(4):849-853. PubMed ID: 36566412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.